Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Brachat, Arndt; Grom, Alexei; Wulffraat, Nico; Brunner, Hermine; Quartier, Pierre; Brik, Riva; McCann, Liza; Ozdogan, Huri; Rutkowska-Sak, Lidia; Schneider, Rayfel; Gerloni, Valeria; Harel, Liora; Terreri, Maria; Houghton, Kristin; Joos, Rik; Kingsbury, Daniel; Lopez-Benitez, Jorge; Bek, Stephan; Schumacher, Martin; Valentin, Marie-Anne; Gram, Hermann; Abrams, Ken; Martini, Alberto; Lovell, Daniel; Nirmala, Nanguneri; Ruperto, Nicolino

doi:10.1186/s13075-016-1212-x

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Atıf İçin Kopyala

Brachat A. H., Grom A. A., Wulffraat N., Brunner H. I., Quartier P., Brik R., ...Daha Fazla

ARTHRITIS RESEARCH & THERAPY, cilt.19, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 19
Basım Tarihi: 2017
Doi Numarası: 10.1186/s13075-016-1212-x
Dergi Adı: ARTHRITIS RESEARCH & THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutralizing IL-1 beta-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA).